{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T08:23:32Z","timestamp":1792225412915,"version":"4.4.0"},"reference-count":171,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Immunol Res"],"DOI":"10.1007\/s12026-026-09806-x","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T06:18:05Z","timestamp":1784009885000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Emerging target antigen landscape for CAR T-cell therapy in solid tumors: current advances and future directions"],"prefix":"10.1007","volume":"74","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-7515-770X","authenticated-orcid":false,"given":"Debolina","family":"Chakraborty","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1055-1485","authenticated-orcid":false,"given":"Subhadip","family":"Kundu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudhir Kumar","family":"Rawal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samson","family":"Mani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,14]]},"reference":[{"key":"9806_CR1","doi-asserted-by":"publisher","unstructured":"Arjumand S, Raj A, Prattay KMR, Omer HBM, Azam F. Chimeric antigen receptor T cell therapy: Revolutionizing cancer treatment. Volume 16. Baishideng Publishing Group Inc.; 2025. p. 108667. [cited 2026 Mar 23]. https:\/\/doi.org\/10.5306\/wjco.v16.i11.108667. World J Clin Oncol.","DOI":"10.5306\/wjco.v16.i11.108667"},{"key":"9806_CR2","doi-asserted-by":"publisher","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","volume":"14","author":"A Mitra","year":"2023","unstructured":"Mitra A, Barua A, Huang L, Ganguly S, Feng Q, He B. From bench to bedside: the history and progress of CAR T cell therapy. Front Immunol Front Media S A. 2023;14:1188049. https:\/\/doi.org\/10.3389\/fimmu.2023.1188049.","journal-title":"Front Immunol Front Media S A"},{"key":"9806_CR3","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/j.xcrm.2025.102353","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: Challenges and breakthroughs. Cell Rep Med Cell Rep Med. 2025;6:102353. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102353. [cited 2026 Feb 21];.","journal-title":"Cell Rep Med Cell Rep Med"},{"key":"9806_CR4","doi-asserted-by":"publisher","unstructured":"Tu Z, Chen Y, Zhang Z, Meng W, Li L. Barriers and solutions for CAR-T therapy in solid tumors. Cancer Gene Therapy. 2025;32:9. Nature Publishing Group. 2025;32:923\u201334. https:\/\/doi.org\/10.1038\/s41417-025-00931-7.\u00a0\u00a0Cited 21 Feb 2026.","DOI":"10.1038\/s41417-025-00931-7"},{"key":"9806_CR5","doi-asserted-by":"publisher","first-page":"6273","DOI":"10.7150\/THNO.76854","volume":"12","author":"Z Liu","year":"2022","unstructured":"Liu Z, Zhou Z, Dang Q, Xu H, Lv J, Li H, et al. Immunosuppression in tumor immune microenvironment and its optimization from CAR-T cell therapy. Theranostics Ivyspring Int Publisher. 2022;12:6273. https:\/\/doi.org\/10.7150\/THNO.76854. [cited 2026 Feb 21];.","journal-title":"Theranostics Ivyspring Int Publisher"},{"key":"9806_CR6","doi-asserted-by":"publisher","unstructured":"Khan TH, Muhammad N, Tarique M, Usmani D, Naz H, Sarode A, Media LLC. 2024;5:61\u20137. https:\/\/doi.org\/10.1007\/s43152-024-00055-4. Cited 23 Mar 2026.","DOI":"10.1007\/s43152-024-00055-4"},{"key":"9806_CR7","doi-asserted-by":"publisher","unstructured":"Xie N, Shen G, Gao W, Huang Z, Huang C, Fu L. Neoantigens: promising targets for cancer therapy. Volume 8. Nature Publishing Group; 2023. pp. 9\u2013. [cited 2026 Mar 23]. https:\/\/doi.org\/10.1038\/s41392-022-01270-x. Signal Transduction and Targeted Therapy 2022 8:1.","DOI":"10.1038\/s41392-022-01270-x"},{"key":"9806_CR8","doi-asserted-by":"publisher","unstructured":"Huber F, Arnaud M, Stevenson BJ, Michaux J, Benedetti F, Thevenet J et al. A comprehensive proteogenomic pipeline for neoantigen discovery to advance personalized cancer immunotherapy. Nat Biotechnol. 2024;43:8. Nature Publishing Group; 2024;43:1360\u201372. https:\/\/doi.org\/10.1038\/s41587-024-02420-y.\u00a0\u00a0Cited 23 Mar 2026.","DOI":"10.1038\/s41587-024-02420-y"},{"key":"9806_CR9","doi-asserted-by":"publisher","unstructured":"Le J, Dian Y, Zhao D, Guo Z, Luo Z, Chen X et al. Single-cell multi-omics in cancer immunotherapy: from tumor heterogeneity to personalized precision treatment. Molecular Cancer 2025;24:1. BioMed Central; 2025;24:221-. https:\/\/doi.org\/10.1186\/s12943-025-02426-3. Cited 23 Mar 2026.","DOI":"10.1186\/s12943-025-02426-3"},{"key":"9806_CR10","doi-asserted-by":"publisher","unstructured":"Wang S, Li X, Ning H, Wu Y. Dual-target CAR-T cell therapy: A new strategy to improve the therapeutic effect of hematological malignancies. Crit Rev Oncol Hematol. Elsevier; 2025;214:104824. https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104824. Cited 23 Mar 2026.","DOI":"10.1016\/j.critrevonc.2025.104824"},{"key":"9806_CR11","doi-asserted-by":"publisher","first-page":"515","DOI":"10.3390\/IJMS21020515","volume":"21","author":"RC Abbott","year":"2020","unstructured":"Abbott RC, Cross RS, Jenkins MR. Finding the Keys to the CAR: Identifying Novel Target Antigens for T Cell Redirection Immunotherapies. Int J Mol Sci MDPI AG. 2020;21:515. https:\/\/doi.org\/10.3390\/IJMS21020515. [cited 2026 May 31];.","journal-title":"Int J Mol Sci MDPI AG"},{"key":"9806_CR12","doi-asserted-by":"publisher","first-page":"1755751","DOI":"10.3389\/FIMMU.2026.1755751","volume":"17","author":"Y Wang","year":"2026","unstructured":"Wang Y, Zhang B, Wang Y, Tan Y, Hu X, Che X, et al. T cell immunotherapy for solid tumors: limitations, progress, and future prospects. Front Immunol Front Media SA. 2026;17:1755751. https:\/\/doi.org\/10.3389\/FIMMU.2026.1755751. [cited 2026 May 31];.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR13","doi-asserted-by":"publisher","unstructured":"Zhang Z, Cui D, Wang H, Wu L, Liu X, Unleashing. CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunol Immunother. Springer Science and Business Media Deutschland GmbH; 2026;75:37. https:\/\/doi.org\/10.1007\/S00262-025-04278-8. Cited 31 Mar 2026.","DOI":"10.1007\/S00262-025-04278-8"},{"key":"9806_CR14","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/s12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int BioMed. 2025;25:313. https:\/\/doi.org\/10.1186\/s12935-025-03938-0. [cited 2026 Feb 23];. Central Ltd.","journal-title":"Cancer Cell Int BioMed"},{"key":"9806_CR15","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1016\/j.trecan.2024.01.003","volume":"10","author":"GJ Kembuan","year":"2024","unstructured":"Kembuan GJ, Kim JY, Maus MV, Jan M. Targeting solid tumor antigens with chimeric receptors: cancer biology meets synthetic immunology. Trends Cancer Elsevier. 2024;10:312\u201331. https:\/\/doi.org\/10.1016\/j.trecan.2024.01.003. [cited 2026 Mar 23];.","journal-title":"Trends Cancer Elsevier"},{"key":"9806_CR16","doi-asserted-by":"publisher","unstructured":"Kundu S, Ray MD, Sharma A. Interplay between genome organization and epigenomic alterations of pericentromeric DNA in cancer. J Gen Genom. Elsevier; 2021;48:184\u201397. https:\/\/doi.org\/10.1016\/j.jgg.2021.02.004. Cited 23 Mar 2026.","DOI":"10.1016\/j.jgg.2021.02.004"},{"key":"9806_CR17","doi-asserted-by":"publisher","first-page":"5110","DOI":"10.1038\/S41467-023-40850-5","volume":"14","author":"Z Xiao","year":"2023","unstructured":"Xiao Z, Todd L, Huang L, Noguera-Ortega E, Lu Z, Huang L, et al. Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors. Nat Commun Nat Res. 2023;14:5110. https:\/\/doi.org\/10.1038\/S41467-023-40850-5. [cited 2026 Jun 30];.","journal-title":"Nat Commun Nat Res"},{"key":"9806_CR18","doi-asserted-by":"publisher","unstructured":"Rezazadeh-Gavgani E, Majidazar R, Lotfinejad P, Kazemi T, Shamekh A. Immune Checkpoint Molecules: A Review on Pathways and Immunotherapy Implications. Immunity, Inflammation and Disease. John Wiley and Sons Inc; 2025;13:e70196. https:\/\/doi.org\/10.1002\/iid3.70196. Cited 23 Mar 2026.","DOI":"10.1002\/iid3.70196"},{"key":"9806_CR19","doi-asserted-by":"publisher","unstructured":"Kuske M, Haist M, Jung T, Grabbe S, Bros M. Immunomodulatory Properties of Immune Checkpoint Inhibitors\u2014More than Boosting T-Cell Responses? Cancers (Basel). MDPI; 2022;14:1710. https:\/\/doi.org\/10.3390\/CANCERS14071710\/S1. Cited 31 Mar 2026.","DOI":"10.3390\/CANCERS14071710\/S1"},{"key":"9806_CR20","doi-asserted-by":"publisher","unstructured":"Biederst\u00e4dt A, Rezvani K. Engineering the next generation of CAR-NK immunotherapies. Int J Hematol. Springer Japan; 2021;114:554. https:\/\/doi.org\/10.1007\/s12185-021-03209-4. Cited 23 Mar 2026.","DOI":"10.1007\/s12185-021-03209-4"},{"key":"9806_CR21","doi-asserted-by":"publisher","unstructured":"Kundu S, Jit BP, Sharma A. Pan-cancer TCGA analysis reveals the potential involvement of B-type lamins in dysregulating chromosome segregation in human cancer. Mammalian Genome 2024 36:1. Springer; 2024;36:230\u201349. https:\/\/doi.org\/10.1007\/s00335-024-10086-9. Cited 23 Mar 2026.","DOI":"10.1007\/s00335-024-10086-9"},{"key":"9806_CR22","doi-asserted-by":"publisher","unstructured":"Aleksander SA, Balhoff JP, Carbon S, Cherry JM, Ebert D, Feuermann M, et al. The Gene Ontology knowledgebase in 2026. Volume 54. Oxford University Press (OUP); 2025. p. D1779. [cited 2026 May 31]. https:\/\/doi.org\/10.1093\/NAR\/GKAF1292. Nucleic Acids Res.","DOI":"10.1093\/NAR\/GKAF1292"},{"key":"9806_CR23","doi-asserted-by":"publisher","unstructured":"He W, Yuan K, He J, Wang C, Peng L, Han Y et al. Network and pathway-based analysis of genes associated with esophageal squamous cell carcinoma. Ann Transl Med. AME Publishing Company; 2023;11:102. https:\/\/doi.org\/10.21037\/ATM-22-6512. Cited 31 Mar 2026.","DOI":"10.21037\/ATM-22-6512"},{"key":"9806_CR24","doi-asserted-by":"publisher","unstructured":"Bartha \u00c1, Gy\u0151rffy B, TNMplot. An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis. Br J Pharmacol. John Wiley and Sons Inc; 2026. https:\/\/doi.org\/10.1111\/BPH.70390. Cited 22 Apr 2026.","DOI":"10.1111\/BPH.70390"},{"key":"9806_CR25","doi-asserted-by":"publisher","unstructured":"Ono K, Fong D, Gao C, Churas C, Pillich R, Lenkiewicz J et al. Cytoscape Web: bringing network biology to the browser. Nucleic Acids Res. Oxford Academic; 2025;53:W203\u201312. https:\/\/doi.org\/10.1093\/NAR\/GKAF365.\u00a0\u00a0Cited 29 May 2026.","DOI":"10.1093\/NAR\/GKAF365"},{"key":"9806_CR26","doi-asserted-by":"publisher","unstructured":"Bartha \u00c1, Gy\u0151rffy B, TNMplot. An enhanced platform for pharmacological target identification through cross-stage and pan-cancer gene expression analysis. Br J Pharmacol. John Wiley and Sons Inc; 2026;183:2648\u201359. https:\/\/doi.org\/10.1111\/BPH.70390. Cited 31 May 2026.","DOI":"10.1111\/BPH.70390"},{"key":"9806_CR27","doi-asserted-by":"publisher","first-page":"12255","DOI":"10.1038\/S41598-026-42544-6","volume":"16","author":"A Yang","year":"2026","unstructured":"Yang A, Luo X, Guo Y, Zhang H, Zhang W, Chang S, et al. The network pharmacology prediction and experiment validation of Astragalus membranaceus for alleviating silicosis fibrosis via decreasing MMP9 and EGFR expression. Sci Rep Nat Res. 2026;16:12255. https:\/\/doi.org\/10.1038\/S41598-026-42544-6. [cited 2026 May 31];.","journal-title":"Sci Rep Nat Res"},{"key":"9806_CR28","doi-asserted-by":"publisher","unstructured":"Kumar S, Kundu S, Sharawat SK, Sharma A. Rewiring cancer epigenome: lncRNA as modulator of chromatin architecture and neoplastic transformation. Mammalian Genome. 2025;37:1. Springer; 2025;37:3-. https:\/\/doi.org\/10.1007\/s00335-025-10172-6. Cited 23 Mar 2026.","DOI":"10.1007\/s00335-025-10172-6"},{"key":"9806_CR29","doi-asserted-by":"publisher","unstructured":"Bur\u010d\u00edk D, Macko J, Podrojkov\u00e1 N, Demeterov\u00e1 J, Stano M, Ori\u0148ak A. Role of Cell Adhesion in Cancer Metastasis Formation: A Review. ACS Omega. American Chemical Society; 2025;10:5193. https:\/\/doi.org\/10.1021\/ACSOMEGA.4C08140. [cited 2026 May 31]","DOI":"10.1021\/ACSOMEGA.4C08140"},{"key":"9806_CR30","doi-asserted-by":"publisher","unstructured":"Bur\u010d\u00edk D, Macko J, Podrojkov\u00e1 N, Demeterov\u00e1 J, Stano M, Ori\u0148ak A. Role of Cell Adhesion in Cancer Metastasis Formation: A Review. ACS Omega. Am Chem Soc. 2025;10:5193. https:\/\/doi.org\/10.1021\/acsomega.4c08140. [cited 2026 Mar 23].","DOI":"10.1021\/acsomega.4c08140"},{"key":"9806_CR31","doi-asserted-by":"publisher","unstructured":"Sanomachi T, Katsuya Y, Nakatsura T, Koyama T, Next-Generation CAR-T, Cell TCR-T. Therapies for Solid Tumors: Innovations, Challenges, and Global Development Trends. Cancers (Basel). Multidisciplinary Digital Publishing Institute (MDPI); 2025;17:1945. https:\/\/doi.org\/10.3390\/cancers17121945. [cited 2026 Mar 23].","DOI":"10.3390\/cancers17121945"},{"key":"9806_CR32","doi-asserted-by":"publisher","unstructured":"Liang R, Liu L, Ding D, Li Y, Ren J, Wei B. CD155 promotes the progression of colorectal cancer by restraining CD8\u2009+\u2009T cells via the PI3K\/AKT\/NF-\u03baB pathway. Cancer Immunology. Volume 74. Springer; 2025. pp. 94\u2013. [cited 2026 May 31]. https:\/\/doi.org\/10.1007\/S00262-025-03947-Y. Immunotherapy 2025 74:3.","DOI":"10.1007\/S00262-025-03947-Y"},{"key":"9806_CR33","doi-asserted-by":"publisher","unstructured":"Qian D, Guo J, Duan Y, Zhou Y, Wu C, Chen Q et al. Immunotherapeutic strategies targeting the PVR\u2013TIGIT\/CD96\/CD226 signaling pathway in glioma treatment. Ann Med. Taylor and Francis Ltd. 2025;57:2588717. https:\/\/doi.org\/10.1080\/07853890.2025.2588717. [cited 2026 May 31].","DOI":"10.1080\/07853890.2025.2588717"},{"key":"9806_CR34","doi-asserted-by":"publisher","unstructured":"Liu K, Liu Y, Xiong H, Ning Z. The Immune Regulatory Functions of CD226 and Its Implications in Immune-Mediated Diseases. Biomolecules. Multidisciplinary Digital Publishing Institute (MDPI). 2025;15:1007. https:\/\/doi.org\/10.3390\/BIOM15071007..","DOI":"10.3390\/BIOM15071007"},{"key":"9806_CR35","doi-asserted-by":"publisher","first-page":"e189920","DOI":"10.1172\/JCI189920","volume":"135","author":"T Xiong","year":"2025","unstructured":"Xiong T, Wang G, Yu P, Li Z, Li D, Zhang J, et al. CAR-T cells targeting CD155 reduce tumor burden in preclinical models of leukemia and solid tumors. J Clin Invest Am Soc Clin Invest. 2025;135:e189920. https:\/\/doi.org\/10.1172\/JCI189920. [cited 2026 May 31].","journal-title":"J Clin Invest Am Soc Clin Invest"},{"key":"9806_CR36","doi-asserted-by":"publisher","unstructured":"Gao J, Zheng Q, Xin N, Wang W, Zhao C. CD155, an onco-immunologic molecule in human tumors. Cancer Sci. Blackwell Publishing Ltd; 2017;108:1934. https:\/\/doi.org\/10.1111\/cas.13324. [cited 2026 Mar 23].","DOI":"10.1111\/cas.13324"},{"key":"9806_CR37","doi-asserted-by":"publisher","unstructured":"Pan C, Zhai Y, Wang C, Liao Z, Di Wang, Yu M et al. Poliovirus receptor\u2013based chimeric antigen receptor T cells combined with NK-92 cells exert potent activity against glioblastoma. JNCI Journal of the National Cancer Institute. Oxford University Press; 2023;116:389. https:\/\/doi.org\/10.1093\/jnci\/djad226. [cited 2026 Mar 23].","DOI":"10.1093\/jnci\/djad226"},{"key":"9806_CR38","doi-asserted-by":"publisher","DOI":"10.1186\/S13073-025-01490-0","author":"X Liu","year":"2025","unstructured":"Liu X, Sun Y, Lin B, Xiong H, Lu X, Tan B, et al. Pan-cancer analysis identifies CD155 as a promising target for CAR-T cell therapy. Genome Med Genome Med. 2025. https:\/\/doi.org\/10.1186\/S13073-025-01490-0. [cited 2026 Feb 21];17.","journal-title":"Genome Med Genome Med"},{"key":"9806_CR39","doi-asserted-by":"publisher","unstructured":"Zhang K, Mi Y, Zhang B, Xue X, Ding Y, Ma J, et al. Preclinical application of a CD155 targeting chimeric antigen receptor T cell therapy for digestive system cancers. Volume 44. Nature Publishing Group; 2025. pp. 1463\u201374. [cited 2026 Mar 23]. https:\/\/doi.org\/10.1038\/s41388-025-03322-2. Oncogene 2025 44:20.","DOI":"10.1038\/s41388-025-03322-2"},{"key":"9806_CR40","doi-asserted-by":"publisher","first-page":"1052672","DOI":"10.3389\/FONC.2022.1052672","volume":"12","author":"Z Qiu","year":"2022","unstructured":"Qiu Z, Wang Y, Zhang Z, Qin R, Peng Y, Tang W, et al. Roles of intercellular cell adhesion molecule-1 (ICAM-1) in colorectal cancer: expression, functions, prognosis, tumorigenesis, polymorphisms and therapeutic implications. Front Oncol Front Media S A. 2022;12:1052672. https:\/\/doi.org\/10.3389\/FONC.2022.1052672. [cited 2026 May 31];.","journal-title":"Front Oncol Front Media S A"},{"key":"9806_CR41","doi-asserted-by":"publisher","unstructured":"Kang JH, Uddin N, Kim S, Zhao Y, Yoo KC, Kim MJ et al. Tumor-intrinsic role of ICAM-1 in driving metastatic progression of triple-negative breast cancer through direct interaction with EGFR. Mol Cancer. 2024;23:1. BioMed Central; 2024;23:230\u2013. https:\/\/doi.org\/10.1186\/S12943-024-02150-4. [cited 2026 May 31].","DOI":"10.1186\/S12943-024-02150-4"},{"key":"9806_CR42","doi-asserted-by":"publisher","first-page":"573823","DOI":"10.3389\/fimmu.2020.573823","volume":"11","author":"H Wei","year":"2020","unstructured":"Wei H, Wang Z, Kuang Y, Wu Z, Zhao S, Zhang Z et al. Intercellular Adhesion Molecule-1 as Target for CAR-T-Cell Therapy of Triple-Negative Breast Cancer. Front Immunol. Frontiers Media S.A. 2020;11:573823\u2013573823. https:\/\/doi.org\/10.3389\/fimmu.2020.573823. [cited 2026 Mar 23].","journal-title":"Front Media S A"},{"key":"9806_CR43","unstructured":"Yang Y, Sanders AJ, Ruge F, Dong X, Cui Y, Dou QP et al. Activated leukocyte cell adhesion molecule (ALCAM)\/CD166 in pancreatic cancer, a pivotal link to clinical outcome and vascular embolism. Am J Cancer Res. 2021;11:5917. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC8727815\/. Accessed 31 May 2026.\u00a0 [cited 2026 May 31]."},{"key":"9806_CR44","doi-asserted-by":"publisher","unstructured":"Wang Y, Yu W, Zhu J, Wang J, Xia K, Liang C et al Anti-CD166\/4-1BB chimeric antigen receptor T cell therapy for the treatment of osteosarcoma. Journal of Experimental & Clinical Cancer Research. Volume 38. BioMed Central Ltd.; 2019. p. 168. https:\/\/doi.org\/10.1186\/s13046-019-1147-6.\u00a0[cited 2026 Mar 27].","DOI":"10.1186\/s13046-019-1147-6"},{"key":"9806_CR45","doi-asserted-by":"publisher","unstructured":"He S, Li S, Guo J, Zeng X, Liang D, Zhu Y et al. CD166-specific CAR-T cells potently target colorectal cancer cells. Transl Oncol. Volume 27. Neoplasia Press, Inc.; 2022. p. 101575. https:\/\/doi.org\/10.1016\/j.tranon.2022.101575. [cited 2026 Mar 27].","DOI":"10.1016\/j.tranon.2022.101575"},{"key":"9806_CR46","doi-asserted-by":"publisher","first-page":"1596460","DOI":"10.3389\/FONC.2025.1596460","volume":"15","author":"W Ji","year":"2025","unstructured":"Ji W, Zhuang X, Jiang WG, Martin TA. Tight junctional protein family, Claudins in cancer and cancer metastasis. Front Oncol Front Media SA. 2025;15:1596460. https:\/\/doi.org\/10.3389\/FONC.2025.1596460. [cited 2026 May 31];.","journal-title":"Front Oncol Front Media SA"},{"key":"9806_CR47","doi-asserted-by":"publisher","first-page":"1596460","DOI":"10.3389\/FONC.2025.1596460\/FULL","volume":"15","author":"W Ji","year":"2025","unstructured":"Ji W, Zhuang X, Jiang WG, Martin TA. Tight junctional protein family, Claudins in cancer and cancer metastasis. Front Oncol Front Media SA. 2025;15:1596460. https:\/\/doi.org\/10.3389\/FONC.2025.1596460\/FULL.","journal-title":"Front Oncol Front Media SA"},{"key":"9806_CR48","doi-asserted-by":"publisher","unstructured":"Lee HJ, Hwang SJ, Jeong EH, Chang MH, Genetically Engineered. CLDN18.2 CAR-T Cells Expressing Synthetic PD1\/CD28 Fusion Receptors Produced Using a Lentiviral Vector. Journal of Microbiology. 2024;62:7. Springer; 2024;62:555\u201368. https:\/\/doi.org\/10.1007\/S12275-024-00133-0","DOI":"10.1007\/S12275-024-00133-0"},{"key":"9806_CR49","doi-asserted-by":"publisher","first-page":"5413","DOI":"10.1158\/1078-0432.CCR-24-1853","volume":"30","author":"AM Barrett","year":"2024","unstructured":"Barrett AM, Britton ZT, Carrasco RA, Breen S, Broggi MAS, Hatke AL, et al. Preclinical Evaluation of AZD6422, an Armored Chimeric Antigen Receptor T Cell Targeting CLDN18.2 in Gastric, Pancreatic, and Esophageal Cancers. Clin Cancer Res Clin Cancer Res. 2024;30:5413\u201329. https:\/\/doi.org\/10.1158\/1078-0432.CCR-24-1853. [cited 2026 Feb 21];.","journal-title":"Clin Cancer Res Clin Cancer Res"},{"key":"9806_CR50","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1158\/2767-9764.CRC-21-0154","volume":"2","author":"M Birtel","year":"2022","unstructured":"Birtel M, Voss RH, Reinhard K, Rengstl B, Ouchan Y, Michel K, et al. A TCR-like CAR Promotes Sensitive Antigen Recognition and Controlled T-cell Expansion Upon mRNA Vaccination. Cancer research communications. Cancer Res Commun. 2022;2:827\u201341. https:\/\/doi.org\/10.1158\/2767-9764.CRC-21-0154. [cited 2026 Feb 21];.","journal-title":"Cancer Res Commun"},{"key":"9806_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2025-011709","author":"PJ Madsen","year":"2025","unstructured":"Madsen PJ, Schlitter AM, Flemmig C, Dickson C, Harvey K, Wilson C, et al. Claudin 6 is a suitable target for CAR T-cell therapy in atypical teratoid\/rhabdoid brain tumors and other pediatric solid tumors. J Immunother Cancer J Immunother Cancer. 2025. https:\/\/doi.org\/10.1136\/JITC-2025-011709. [cited 2026 Jan 3];13.","journal-title":"J Immunother Cancer J Immunother Cancer"},{"key":"9806_CR52","doi-asserted-by":"crossref","unstructured":"Han Y, Liu D, Li L. PD-1\/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10:727. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC7136921\/. Accessed 21 Feb 2026.\u00a0[cited 2026 Feb 21].","DOI":"10.1186\/s12935-021-02287-y"},{"key":"9806_CR53","doi-asserted-by":"publisher","unstructured":"Li D, English H, Hong J, Liang T, Merlino G, Day CP et al. A novel PD-L1-targeted shark VNAR single-domain-based CAR-T cell strategy for treating breast cancer and liver cancer. Mol Ther Oncolytics. Cell Press; 2022;24:849\u201363. https:\/\/doi.org\/10.1016\/j.omto.2022.02.015. [cited 2026 Jan 9].","DOI":"10.1016\/j.omto.2022.02.015"},{"key":"9806_CR54","doi-asserted-by":"publisher","unstructured":"Zhou JT, Liu JH, Song TT, Ma B, Amidula N, Bai C, EGLIF-CAR-T Cells Secreting. PD-1 Blocking Antibodies Significantly Mediate the Elimination of Gastric Cancer. Cancer Manag Res. Volume 12. Dove Medical Press Ltd; 2020. p. 8893. https:\/\/doi.org\/10.2147\/CMAR.S260915. [cited 2026 Mar 23].","DOI":"10.2147\/CMAR.S260915"},{"key":"9806_CR55","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/NBT.4195;TECHMETA","volume":"36","author":"S Rafiq","year":"2018","unstructured":"Rafiq S, Yeku OO, Jackson HJ, Purdon TJ, van Leeuwen DG, Drakes DJ, et al. Targeted delivery of a PD-1-blocking scFV by CAR-T cells enhances anti-tumor efficacy in vivo. Nat Biotechnol Nat. 2018;36:847\u201358. https:\/\/doi.org\/10.1038\/NBT.4195;TECHMETA. [cited 2026 Feb 21];. Publishing Group.","journal-title":"Nat Biotechnol Nat"},{"key":"9806_CR56","doi-asserted-by":"publisher","first-page":"803","DOI":"10.3389\/fcell.2020.00803","volume":"8","author":"Y Ping","year":"2020","unstructured":"Ping Y, Li F, Nan S, Zhang D, Shi X, Shan J, et al. Augmenting the Effectiveness of CAR-T Cells by Enhanced Self-Delivery of PD-1-Neutralizing scFv. Front Cell Dev Biol Front Media S A. 2020;8:803. https:\/\/doi.org\/10.3389\/fcell.2020.00803. [cited 2026 Mar 23];.","journal-title":"Front Cell Dev Biol Front Media S A"},{"key":"9806_CR57","doi-asserted-by":"publisher","unstructured":"Guo Y, Wang X, Zhang C, Chen W, Fu Y, Yu Y, et al. Tumor Immunotherapy Targeting B7-H3: From Mechanisms to Clinical Applications. Immunotargets Ther. Volume 14. Dove Medical Press Ltd; 2025. p. 291. https:\/\/doi.org\/10.2147\/ITT.S507522. [cited 2026 Feb 21].","DOI":"10.2147\/ITT.S507522"},{"key":"9806_CR58","doi-asserted-by":"publisher","unstructured":"Du H, Hirabayashi K, Ahn S, Kren NP, Montgomery SA, Wang X, et al. Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. Cancer Cell. 2019;35:221\u2013e2378. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.002. [cited 2026 Jan 9].","DOI":"10.1016\/j.ccell.2019.01.002"},{"key":"9806_CR59","doi-asserted-by":"publisher","unstructured":"Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid\/rhabdoid tumors. Nat Med. 2020;26:5. Nature Publishing Group; 2020;26:712\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0821-8. [cited 2026 Jan 9].","DOI":"10.1038\/s41591-020-0821-8"},{"key":"9806_CR60","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.2340\/1651-226X.2025.43587","volume":"64","author":"S B\u00fcy\u00fccek","year":"2025","unstructured":"B\u00fcy\u00fccek S, Lurati M, M\u00f6ller K, Viehweger F, Schlichter R, Menz A, et al. L1CAM\/CD171 expression in human tumors and its association with tumor phenotype. Acta Oncol Acta Oncol. 2025;64:1621\u201330. https:\/\/doi.org\/10.2340\/1651-226X.2025.43587. [cited 2026 May 31];.","journal-title":"Acta Oncol Acta Oncol"},{"key":"9806_CR61","doi-asserted-by":"publisher","first-page":"1677361","DOI":"10.3389\/FIMMU.2025.1677361\/FULL","volume":"16","author":"L Andersch","year":"2025","unstructured":"Andersch L, Grunewald L, Stecklum M, Klironomos F, Haase K, Hollek V, et al. Investigating genetic modifications to enhance L1CAM-CAR T cell migration in solid tumors in a 3D bioprinted neuroblastoma model. Front Immunol Front Media SA. 2025;16:1677361. https:\/\/doi.org\/10.3389\/FIMMU.2025.1677361\/FULL. [cited 2026 May 31];.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR62","doi-asserted-by":"publisher","unstructured":"Andersch L, Radke J, Klaus A, Schwiebert S, Winkler A, Schumann E, et al. CD171- and GD2-specific CAR-T cells potently target retinoblastoma cells in preclinical in vitro testing. BMC Cancer. Volume 19. BioMed Central Ltd.; 2019. p. 895. https:\/\/doi.org\/10.1186\/s12885-019-6131-1. [cited 2026 Mar 27].","DOI":"10.1186\/s12885-019-6131-1"},{"key":"9806_CR63","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1158\/1078-0432.CCR-16-0354","volume":"23","author":"A K\u00fcnkele","year":"2017","unstructured":"K\u00fcnkele A, Taraseviciute A, Finn LS, Johnson AJ, Berger C, Finney O, et al. Preclinical assessment of CD171-directed CAR T-cell adoptive therapy for childhood neuroblastoma: CE7 epitope target safety and product manufacturing feasibility. Clin Cancer Res Am Association Cancer Res Inc. 2017;23:466\u201377. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0354. [cited 2026 Mar 27].","journal-title":"Clin Cancer Res Am Association Cancer Res Inc"},{"key":"9806_CR64","doi-asserted-by":"publisher","unstructured":"Shah NN, Sokol L. Targeting CD22 for the Treatment of B-Cell Malignancies. Immunotargets Ther. Volume 10. Dove Medical Press Ltd; 2021. p. 225. [cited 2026 May 31]. https:\/\/doi.org\/10.2147\/ITT.S288546.","DOI":"10.2147\/ITT.S288546"},{"key":"9806_CR65","doi-asserted-by":"publisher","unstructured":"Frank MJ, Baird JH, Kramer AM, Srinagesh HK, Patel S, Brown AK, Elsevier BV et al. 2024;404:353\u201363. https:\/\/doi.org\/10.1016\/S0140-6736(24)00746-3. [cited 2026 Jun 30]","DOI":"10.1016\/S0140-6736(24)00746-3"},{"key":"9806_CR66","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1158\/2326-6066.CIR-20-0675","volume":"9","author":"G Wei","year":"2021","unstructured":"Wei G, Zhang Y, Zhao H, Wang Y, Liu Y, Liang B, et al. CD19\/CD22 Dual-Targeted CAR T-cell Therapy for Relapsed\/Refractory Aggressive B-cell Lymphoma: A Safety and Efficacy Study. Cancer Immunol Res Cancer Immunol Res. 2021;9:1061\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-20-0675. [cited 2026 Mar 27];.","journal-title":"Cancer Immunol Res Cancer Immunol Res"},{"key":"9806_CR67","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-023-04409-8","author":"T Liu","year":"2023","unstructured":"Liu T, Dai X, Xu Y, Guan T, Hong L, Zaib T, et al. CD22 is a potential target of CAR-NK cell therapy for esophageal squamous cell carcinoma. J Transl Med J Transl Med. 2023. https:\/\/doi.org\/10.1186\/s12967-023-04409-8. [cited 2026 Mar 27];21.","journal-title":"J Transl Med J Transl Med"},{"key":"9806_CR68","doi-asserted-by":"publisher","unstructured":"Liao W, Zai X, Zhang J, Xu J. Hematopoietic stem cell state and fate in trained immunity. Cell Commun Signaling. 2025;23:1. BioMed Central; 2025;23:182-. https:\/\/doi.org\/10.1186\/S12964-025-02192-1. [cited 2026 May 31]","DOI":"10.1186\/S12964-025-02192-1"},{"key":"9806_CR69","doi-asserted-by":"publisher","unstructured":"He K, Liu X, Hoffman RD, Shi RZ, Lv GY, Gao JL. G-CSF\/GM\u2010CSF\u2010induced hematopoietic dysregulation in the progression of solid tumors. Volume 12. John Wiley and Sons Inc; 2022. p. 1268. [cited 2026 May 31]. https:\/\/doi.org\/10.1002\/2211-5463.13445. FEBS Open Bio.","DOI":"10.1002\/2211-5463.13445"},{"key":"9806_CR70","doi-asserted-by":"publisher","first-page":"56219","DOI":"10.18632\/oncotarget.11019","volume":"7","author":"KH Chen","year":"2016","unstructured":"Chen KH, Wada M, Firor AE, Pinz KG, Jares A, Liu H, et al. Novel anti-CD3 chimeric antigen receptor targeting of aggressive T cell malignancies. Oncotarget Impact Journals LLC. 2016;7:56219. https:\/\/doi.org\/10.18632\/oncotarget.11019. [cited 2026 Mar 27];.","journal-title":"Oncotarget Impact Journals LLC"},{"key":"9806_CR71","doi-asserted-by":"publisher","unstructured":"Ishiguro T, Sano Y, Komatsu SI, Kamata-Sakurai M, Kaneko A, Kinoshita Y et al. An anti-glypican 3\/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors. Sci Transl Med. Am Assoc Advan Sci. 2017;9. https:\/\/doi.org\/10.1126\/scitranslmed.aal4291. [cited 2026 Mar 27].","DOI":"10.1126\/scitranslmed.aal4291"},{"key":"9806_CR72","doi-asserted-by":"publisher","unstructured":"Porcellini S, Asperti C, Corna S, Cicoria E, Valtolina V, Stornaiuolo A et al. CAR T Cells Redirected to CD44v6 Control Tumor Growth in Lung and Ovary Adenocarcinoma Bearing Mice. Front Immunol. Frontiers Media S.A. 2020;11:497408. https:\/\/doi.org\/10.3389\/FIMMU.2020.00099\/TEXT. [cited 2026 Jun 30].","DOI":"10.3389\/FIMMU.2020.00099\/TEXT"},{"key":"9806_CR73","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/S00262-003-0494-4","volume":"53","author":"KH Heider","year":"2004","unstructured":"Heider KH, Kuthan H, Stehle G, Munzert G. CD44v6: a target for antibody-based cancer therapy. Cancer Immunol Immunother. 2004;53:567. https:\/\/doi.org\/10.1007\/S00262-003-0494-4. [cited 2026 Jun 30];.","journal-title":"Cancer Immunol Immunother"},{"key":"9806_CR74","doi-asserted-by":"publisher","DOI":"10.1016\/J.ORALONCOLOGY.2021.105259","author":"C Haist","year":"2021","unstructured":"Haist C, Schulte E, Bartels N, Bister A, Poschinski Z, Ibach TC, et al. CD44v6-targeted CAR T-cells specifically eliminate CD44 isoform 6 expressing head\/neck squamous cell carcinoma cells. Oral Oncol Oral Oncol. 2021. https:\/\/doi.org\/10.1016\/J.ORALONCOLOGY.2021.105259. [cited 2026 Jun 30];116.","journal-title":"Oral Oncol Oral Oncol"},{"key":"9806_CR75","doi-asserted-by":"publisher","unstructured":"Maher J. Chimeric Antigen Receptor (CAR) T-Cell Therapy for Patients with Lung Cancer: Current Perspectives. Onco Targets Ther. Volume 16. Dove Medical Press Ltd; 2023. p. 515. [cited 2026 Jun 30]. https:\/\/doi.org\/10.2147\/OTT.S341179.","DOI":"10.2147\/OTT.S341179"},{"key":"9806_CR76","doi-asserted-by":"publisher","unstructured":"Wang H, Ye X, Ju Y, Cai Z, Wang X, Du P, et al. Minicircle DNA-Mediated CAR T Cells Targeting CD44 Suppressed Hepatocellular Carcinoma Both in vitro and in vivo. Onco Targets Ther. Volume 13. Dove Medical Press Ltd.; 2020. p. 3703. [cited 2026 Jan 2]. https:\/\/doi.org\/10.2147\/OTT.S247836.","DOI":"10.2147\/OTT.S247836"},{"key":"9806_CR77","doi-asserted-by":"publisher","first-page":"1506204","DOI":"10.3389\/FIMMU.2025.1506204\/BIBTEX","volume":"16","author":"H Ogawa","year":"2025","unstructured":"Ogawa H, Ekawa T, Mizote Y, Akazawa T, Tahara H. Relaxin-2-secreting CAR-T cells exhibit enhanced efficacy in stromal-rich xenograft tumors. Front Immunol Front Media SA. 2025;16:1506204. https:\/\/doi.org\/10.3389\/FIMMU.2025.1506204\/BIBTEX.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR78","doi-asserted-by":"publisher","first-page":"1290488","DOI":"10.3389\/FIMMU.2023.1290488\/FULL","volume":"14","author":"IS Ciulean","year":"2023","unstructured":"Ciulean IS, Fischer J, Quaiser A, Bach C, Abken H, Tretbar US, et al. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol Front Media SA. 2023;14:1290488. https:\/\/doi.org\/10.3389\/FIMMU.2023.1290488\/FULL. [cited 2026 Jun 30];.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR79","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1016\/J.CCELL.2025.03.019","volume":"43","author":"B Du","year":"2025","unstructured":"Du B, Qin J, Lin B, Zhang J, Li D, Liu M. CAR-T therapy in solid tumors. Cancer Cell Cell Press. 2025;43:665\u201379. https:\/\/doi.org\/10.1016\/J.CCELL.2025.03.019. [cited 2026 Jun 30];.","journal-title":"Cancer Cell Cell Press"},{"key":"9806_CR80","doi-asserted-by":"publisher","first-page":"102353","DOI":"10.1016\/J.XCRM.2025.102353","volume":"6","author":"G Escobar","year":"2025","unstructured":"Escobar G, Berger TR, Maus MV. CAR-T cells in solid tumors: Challenges and breakthroughs. Cell Rep Med. 2025;6:102353. https:\/\/doi.org\/10.1016\/J.XCRM.2025.102353. [cited 2026 Jun 30];.","journal-title":"Cell Rep Med"},{"key":"9806_CR81","doi-asserted-by":"publisher","first-page":"e0247701","DOI":"10.1371\/JOURNAL.PONE.0247701","volume":"16","author":"C Ambrose","year":"2021","unstructured":"Ambrose C, Su L, Wu L, Dufort FJ, Sanford T, Birt A, et al. Anti-CD19 CAR T cells potently redirected to kill solid tumor cells. PLoS One Public Libr Sci. 2021;16:e0247701. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0247701. [cited 2026 Jun 30];.","journal-title":"PLoS One Public Libr Sci"},{"key":"9806_CR82","doi-asserted-by":"publisher","DOI":"10.1073\/PNAS.2518996122","author":"AV Finck","year":"2025","unstructured":"Finck AV, Wang Z, Gonzales D, Wellhausen N, Castelli S, Banerjee E, et al. Dual-targeted ping-pong CAR T cells: Leveraging peripheral expansion to improve solid tumor immunotherapy. Proc Natl Acad Sci U S A. Proc Natl Acad Sci U S A. 2025. https:\/\/doi.org\/10.1073\/PNAS.2518996122. [cited 2026 Jun 30];122.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"9806_CR83","doi-asserted-by":"publisher","first-page":"e0161820","DOI":"10.1371\/JOURNAL.PONE.0161820","volume":"11","author":"SH Du","year":"2016","unstructured":"Du SH, Li Z, Chen C, Tan WK, Chi Z, Kwang TW, et al. Co-Expansion of Cytokine-Induced Killer Cells and V\u03b39V\u03b42 T Cells for CAR T-Cell Therapy. PLoS One Public Libr Sci. 2016;11:e0161820. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0161820. [cited 2025 Dec 29];.","journal-title":"PLoS One Public Libr Sci"},{"key":"9806_CR84","doi-asserted-by":"publisher","unstructured":"Mikoli\u010d V, Pantovi\u0107-\u017dalig J, Malen\u0161ek \u0160, Sever M, Lain\u0161\u010dek D, Jerala R. Toll-like receptor 4 signaling activation domains promote CAR T cell function against solid tumors. Molecular Therapy Oncology. Cell Press; 2024;32. https:\/\/doi.org\/10.1016\/j.omton.2024.200815. [cited 2026 Feb 21].","DOI":"10.1016\/j.omton.2024.200815"},{"key":"9806_CR85","doi-asserted-by":"publisher","unstructured":"Dong A, Soleimani Samarkhazan H, Tavakoli F, Beyond CRISPR. next-gen precision engineering of CAR-NK cells for enhanced persistence, trafficking, and tumor eradication. Cancer Cell Int. BioMed Central Ltd; 2026;26:120. https:\/\/doi.org\/10.1186\/S12935-026-04219-0. [cited 2026 Jun 30].","DOI":"10.1186\/S12935-026-04219-0"},{"key":"9806_CR86","doi-asserted-by":"publisher","first-page":"5891","DOI":"10.2147\/IJN.S424723","volume":"18","author":"PHDM Prazeres","year":"2023","unstructured":"Prazeres PHDM, Ferreira H, Costa PAC, da Silva W, Alves MT, Padilla M, et al. Delivery of Plasmid DNA by Ionizable Lipid Nanoparticles to Induce CAR Expression in T Cells. Int J Nanomed Int J Nanomed. 2023;18:5891\u2013904. https:\/\/doi.org\/10.2147\/IJN.S424723. [cited 2026 Feb 21];.","journal-title":"Int J Nanomed Int J Nanomed"},{"key":"9806_CR87","doi-asserted-by":"publisher","unstructured":"Zhang Y, Li C, Du M, Jiang H, Luo W, Tang L et al. Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies. Blood Cancer Journal. 2023;13:1. Nature Publishing Group; 2023;13:61-. https:\/\/doi.org\/10.1038\/s41408-023-00822-w. [cited 2026 Jun 30].","DOI":"10.1038\/s41408-023-00822-w"},{"key":"9806_CR88","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1182\/BLOOD-2017-01-761320","volume":"130","author":"D Gomes-Silva","year":"2017","unstructured":"Gomes-Silva D, Srinivasan M, Sharma S, Lee CM, Wagner DL, Davis TH, et al. CD7-edited T cells expressing a CD7-specific CAR for the therapy of T-cell malignancies. Blood Am Soc Hematol. 2017;130:285. https:\/\/doi.org\/10.1182\/BLOOD-2017-01-761320. [cited 2026 Jun 30];.","journal-title":"Blood Am Soc Hematol"},{"key":"9806_CR89","doi-asserted-by":"publisher","first-page":"1478888","DOI":"10.3389\/FONC.2024.1478888\/TEXT","volume":"14","author":"J Liu","year":"2024","unstructured":"Liu J, An Y, Sun R, Zhang X, Guo S, Gao X, et al. The efficacy and safety of CD7 chimeric antigen receptor T-cell therapy for hematologic malignancies: a systematic review and meta-analysis. Front Oncol Front Media SA. 2024;14:1478888. https:\/\/doi.org\/10.3389\/FONC.2024.1478888\/TEXT. [cited 2026 Jun 30];.","journal-title":"Front Oncol Front Media SA"},{"key":"9806_CR90","doi-asserted-by":"publisher","first-page":"e16961","DOI":"10.1016\/j.heliyon.2023.e16961","volume":"9","author":"B Sheng","year":"2023","unstructured":"Sheng B, Zhang K, Tian S, Ma R, Li Z, Wu H, et al. CD7 protein plays a crucial role in T cell infiltration in tumors. Heliyon Elsevier. 2023;9:e16961. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e16961. [cited 2026 Mar 23];.","journal-title":"Heliyon Elsevier"},{"key":"9806_CR91","doi-asserted-by":"publisher","first-page":"3191","DOI":"10.1007\/s00262-023-03491-7","volume":"72","author":"P Yang","year":"2023","unstructured":"Yang P, Yu F, Yao Z, Ding X, Xu H, Zhang J. CD24 is a novel target of chimeric antigen receptor T cells for the treatment of triple negative breast cancer. Cancer Immunol Immunother Springer Sci Bus Media Deutschland GmbH. 2023;72:3191. https:\/\/doi.org\/10.1007\/s00262-023-03491-7. [cited 2026 Mar 27];.","journal-title":"Cancer Immunol Immunother Springer Sci Bus Media Deutschland GmbH"},{"key":"9806_CR92","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1158\/1535-7163.MCT-24-0597","volume":"24","author":"Y Huang","year":"2025","unstructured":"Huang Y, Yang X, Li J, Zhou W, Wang F, Li J, et al. CD24-Targeted CAR-T Cells Mediated Long-term Antitumor Efficacy through Activation of Endogenous Tumor Immune Responses. Mol Cancer Ther Mol Cancer Ther. 2025;24:1075\u201387. https:\/\/doi.org\/10.1158\/1535-7163.MCT-24-0597. [cited 2026 Mar 27];.","journal-title":"Mol Cancer Ther Mol Cancer Ther"},{"key":"9806_CR93","doi-asserted-by":"publisher","unstructured":"Sun F, Cheng Y, Wanchai V, Guo W, Mery D, Xu H et al. Bispecific BCMA\/CD24 CAR-T cells control multiple myeloma growth. Nat Commun. 2024;15:1. Nature Publishing Group; 2024;15:615-. https:\/\/doi.org\/10.1038\/s41467-024-44873-4. [cited 2026 Mar 27].","DOI":"10.1038\/s41467-024-44873-4"},{"key":"9806_CR94","doi-asserted-by":"publisher","first-page":"16024","DOI":"10.1038\/MTO.2016.24","volume":"3","author":"K Inoo","year":"2016","unstructured":"Inoo K, Inagaki R, Fujiwara K, Sasawatari S, Kamigaki T, Nakagawa S, et al. Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research. Mol Ther Oncolytics Elsevier. 2016;3:16024. https:\/\/doi.org\/10.1038\/MTO.2016.24. [cited 2025 Dec 29];.","journal-title":"Mol Ther Oncolytics Elsevier"},{"key":"9806_CR95","doi-asserted-by":"publisher","first-page":"970","DOI":"10.1038\/GT.2013.19","volume":"20","author":"W Wang","year":"2013","unstructured":"Wang W, Ma Y, Li J, Shi HS, Wang LQ, Guo FC, et al. Specificity redirection by CAR with human VEGFR-1 affinity endows T lymphocytes with tumor-killing ability and anti-angiogenic potency. Gene Ther Gene Ther. 2013;20:970\u20138. https:\/\/doi.org\/10.1038\/GT.2013.19. [cited 2026 Feb 21];.","journal-title":"Gene Ther Gene Ther"},{"key":"9806_CR96","doi-asserted-by":"publisher","unstructured":"Hajari Taheri F, Hassani M, Sharifzadeh Z, Behdani M, Arashkia A, Abolhassani M. T cell engineered with a novel nanobody-based chimeric antigen receptor against VEGFR2 as a candidate for tumor immunotherapy. IUBMB Life. IUBMB Life; 2019;71:1259\u201367. https:\/\/doi.org\/10.1002\/IUB.2019. [cited 2026 Jan 2].","DOI":"10.1002\/IUB.2019"},{"key":"9806_CR97","doi-asserted-by":"publisher","unstructured":"Taheri FH, Hassani M, Sharifzadeh Z, Behdani M, Abdoli S, Sayadi M et al. Tuning spacer length improves the functionality of the nanobody-based VEGFR2 CAR T cell. BMC Biotechnol. 2024;24:1. BioMed Central; 2024;24:1-. https:\/\/doi.org\/10.1186\/S12896-023-00827-0. [cited 2026 Feb 21].","DOI":"10.1186\/S12896-023-00827-0"},{"key":"9806_CR98","doi-asserted-by":"publisher","unstructured":"Thayaparan T, Petrovic RM, Achkova DY, Zabinski T, Davies DM, Klampatsa A, et al. CAR T-cell immunotherapy of MET-expressing malignant mesothelioma. Oncoimmunology. Volume 6. Taylor and Francis Inc.; 2017. p. e1363137. [cited 2026 Mar 27]. https:\/\/doi.org\/10.1080\/2162402X.2017.1363137.","DOI":"10.1080\/2162402X.2017.1363137"},{"key":"9806_CR99","doi-asserted-by":"publisher","unstructured":"Qin A, Musket A, Hilton B, Preiszner J, Krenciute G, Berens ME et al. Efficacy of MET-targeting CAR T cells against glioblastoma patient-derived xenograft models. J Transl Med. BioMed Central Ltd; 2025;23:460. https:\/\/doi.org\/10.1186\/s12967-025-06475-6. [cited 2026 Mar 27].","DOI":"10.1186\/s12967-025-06475-6"},{"key":"9806_CR100","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1186\/s12967-023-04521-9","volume":"21","author":"A Qin","year":"2023","unstructured":"Qin A, Qin Y, Lee J, Musket A, Ying M, Krenciute G, et al. Tyrosine kinase signaling-independent MET-targeting with CAR-T cells. J Transl Med BioMed. 2023;21:682. https:\/\/doi.org\/10.1186\/s12967-023-04521-9. [cited 2026 Mar 27];. Central Ltd.","journal-title":"J Transl Med BioMed"},{"key":"9806_CR101","doi-asserted-by":"publisher","first-page":"11110","DOI":"10.3390\/IJMS241311110","volume":"24","author":"SMB Rodriguez","year":"2023","unstructured":"Rodriguez SMB, Kamel A, Ciubotaru GV, Onose G, Sevastre AS, Sfredel V, et al. An Overview of EGFR Mechanisms and Their Implications in Targeted Therapies for Glioblastoma. Int J Mol Sci. 2023;24:11110. https:\/\/doi.org\/10.3390\/IJMS241311110. [cited 2026 Jun 30];. Multidisciplinary Digital Publishing Institute (MDPI).","journal-title":"Int J Mol Sci"},{"key":"9806_CR102","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/J.MEDJ.2022.05.001","volume":"3","author":"F Korell","year":"2022","unstructured":"Korell F, Berger TR, Maus MV. Understanding CAR T cell-tumor interactions: Paving the way for successful clinical outcomes. Med Cell Press. 2022;3:538\u201364. https:\/\/doi.org\/10.1016\/J.MEDJ.2022.05.001. [cited 2026 Jun 30].","journal-title":"Med Cell Press"},{"key":"9806_CR103","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1038\/s41587-019-0192-1","volume":"37","author":"BD Choi","year":"2019","unstructured":"Choi BD, Yu X, Castano AP, Bouffard AA, Schmidts A, Larson RC, et al. CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity. Nat Biotechnol Nat Biotechnol. 2019;37:1049\u201358. https:\/\/doi.org\/10.1038\/s41587-019-0192-1. [cited 2026 Mar 27];.","journal-title":"Nat Biotechnol Nat Biotechnol"},{"issue":"1","key":"9806_CR104","doi-asserted-by":"publisher","first-page":"11593","DOI":"10.1038\/s41467-025-66737-1","volume":"16","author":"R Murray","year":"2025","unstructured":"Murray R, Chowdhury MR, Botticello-Romero NR, et al. Multiplex gene-editing strategy to engineer allogeneic EGFR-targeting CAR T-cells with improved efficacy against solid tumors. Nat Commun. 2025;16(1):11593. https:\/\/doi.org\/10.1038\/s41467-025-66737-1","journal-title":"Nat Commun"},{"key":"9806_CR105","doi-asserted-by":"publisher","unstructured":"Fumagalli M, An D, Simula L, Combe C, Aziez L, Simoni Y et al. An in vivo CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor model. bioRxiv. Cold Spring Harbor Laboratory; 2025;2025.03.28.645780. https:\/\/doi.org\/10.1101\/2025.03.28.645780. [cited 2026 Feb 14].","DOI":"10.1101\/2025.03.28.645780"},{"key":"9806_CR106","doi-asserted-by":"publisher","unstructured":"Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H et al. Therapeutic Efficacy of IL7\/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Cancer Research Communications. American Association for Cancer Research Inc. 2024;4:2514\u201324. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0226\/747929\/AM\/THERAPEUTIC-EFFICACY-OF-IL-7-CCL19-EXPRESSING-CAR. [cited 2026 Jan 9].","DOI":"10.1158\/2767-9764.CRC-24-0226\/747929\/AM\/THERAPEUTIC-EFFICACY-OF-IL-7-CCL19-EXPRESSING-CAR"},{"key":"9806_CR107","doi-asserted-by":"publisher","unstructured":"Song Y, Tong C, Wang Y, Gao Y, Dai H, Guo Y, et al. Effective and persistent antitumor activity of HER2-directed CAR-T cells against gastric cancer cells in vitro and xenotransplanted tumors in vivo. Protein Cell. Volume 9. Higher Education Press; 2017. p. 867. [cited 2026 Feb 21]. https:\/\/doi.org\/10.1007\/S13238-017-0384-8.","DOI":"10.1007\/S13238-017-0384-8"},{"key":"9806_CR108","doi-asserted-by":"publisher","unstructured":"Ohta K, Sakoda Y, Adachi K, Shinozaki T, Nakajima M, Yasuda H, et al. Therapeutic Efficacy of IL7\/CCL19-Expressing CAR-T Cells in Intractable Solid Tumor Models of Glioblastoma and Pancreatic Cancer. Cancer Research Communications. Volume 4. American Association for Cancer Research Inc.; 2024. p. 2514. [cited 2026 Mar 27]. https:\/\/doi.org\/10.1158\/2767-9764.CRC-24-0226.","DOI":"10.1158\/2767-9764.CRC-24-0226"},{"key":"9806_CR109","doi-asserted-by":"publisher","unstructured":"Andreu-Saumell I, Rodriguez-Garcia A, M\u00fchlgrabner V, Gimenez-Alejandre M, Marzal B, Castellsagu\u00e9 J et al. CAR affinity modulates the sensitivity of CAR-T cells to PD-1\/PD-L1-mediated inhibition. Nat Commun. 2024;15:1. Nature Publishing Group; 2024;15:3552-. https:\/\/doi.org\/10.1038\/s41467-024-47799-z. [cited 2026 Feb 14].","DOI":"10.1038\/s41467-024-47799-z"},{"key":"9806_CR110","doi-asserted-by":"publisher","unstructured":"Tang N, Cheng L, Hao J, Xu B, Pan X, Wei X et al. Development of CAR-T cell therapy for NF1\/SWN-related nerve sheath tumor treatment. Acta Neuropathol Commun. BioMed Central Ltd; 2025;13:45. https:\/\/doi.org\/10.1186\/S40478-025-01965-6. [cited 2026 Jan 9].","DOI":"10.1186\/S40478-025-01965-6"},{"key":"9806_CR111","doi-asserted-by":"publisher","DOI":"10.1136\/JITC-2023-008665","author":"K Nakagawara","year":"2024","unstructured":"Nakagawara K, Ando M, Srirat T, Mise-Omata S, Hayakawa T, Ito M, et al. NR4A ablation improves mitochondrial fitness for long persistence in human CAR-T cells against solid tumors. J Immunother Cancer J Immunother Cancer. 2024. https:\/\/doi.org\/10.1136\/JITC-2023-008665. [cited 2026 Feb 14];12.","journal-title":"J Immunother Cancer J Immunother Cancer"},{"key":"9806_CR112","doi-asserted-by":"publisher","DOI":"10.1016\/j.omton.2025.201088","author":"F Meeus","year":"2025","unstructured":"Meeus F, Van der Vreken A, Autaers D, De Groof TWM, Esprit A, Franceschini L, et al. Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors. Mol Therapy Oncol Cell Press. 2025. https:\/\/doi.org\/10.1016\/j.omton.2025.201088. [cited 2026 Feb 21];33.","journal-title":"Mol Therapy Oncol Cell Press"},{"key":"9806_CR113","doi-asserted-by":"publisher","unstructured":"Mata M, Gerken C, Nguyen P, Krenciute G, Spencer DM, Gottschalk S. Inducible activation of myD88 and CD40 in CAR T cells results in controllable and potent antitumor activity in preclinical solid tumor models. Cancer Discov. American Association for Cancer Research Inc. 2017;7:1306\u201319. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-0263. [cited 2026 Mar 23].","DOI":"10.1158\/2159-8290.CD-17-0263"},{"key":"9806_CR114","doi-asserted-by":"publisher","unstructured":"Yadav M, Sharma A, Patne K, Tabasum S, Suryavanshi J, Rawat L, et al. AXL signaling in cancer: from molecular insights to targeted therapies. Signal Transduction and Targeted Therapy 2025 10:1. Volume 10. Nature Publishing Group; 2025. pp. 37\u2013. [cited 2026 Feb 21]. https:\/\/doi.org\/10.1038\/s41392-024-02121-7.","DOI":"10.1038\/s41392-024-02121-7"},{"key":"9806_CR115","doi-asserted-by":"publisher","unstructured":"Zou B, Wang M, Bai S, Li N, Fan Z, Peng Y et al. Novel mRNA-Engineered Fully Human CAR-T Cells Targeting AXL in Solid Tumors. Biomedicines. Biomed. 2025;13. https:\/\/doi.org\/10.3390\/BIOMEDICINES13040844. [cited 2026 Jan 2].","DOI":"10.3390\/BIOMEDICINES13040844"},{"key":"9806_CR116","doi-asserted-by":"publisher","first-page":"3448","DOI":"10.3390\/ijms19113448","volume":"19","author":"H Huang","year":"2018","unstructured":"Huang H. Anaplastic Lymphoma Kinase (ALK) Receptor Tyrosine Kinase: A Catalytic Receptor with Many Faces. Int J Mol Sci. 2018;19:3448. https:\/\/doi.org\/10.3390\/ijms19113448. [cited 2026 Feb 23];. MDPI AG.","journal-title":"Int J Mol Sci"},{"key":"9806_CR117","doi-asserted-by":"publisher","unstructured":"Halliwell E, Vitali A, Muller H, Alonso-Ferrero M, Barisa M, Gavriil A et al. Targeting of low ALK antigen density neuroblastoma using AND logic-gate engineered CAR-T cells. Cytotherapy. Elsevier B.V.; 2023;25:46\u201358. https:\/\/doi.org\/10.1016\/j.jcyt.2022.10.007. [cited 2026 Jan 9].","DOI":"10.1016\/j.jcyt.2022.10.007"},{"key":"9806_CR118","doi-asserted-by":"publisher","unstructured":"Walker AJ, Majzner RG, Zhang L, Wanhainen K, Long AH, Nguyen SM et al. Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. Molecular Therapy. Am Soc Gene Cell Therapy. 2017;25:2189. https:\/\/doi.org\/10.1016\/j.ymthe.2017.06.008. [cited 2026 Mar 23].","DOI":"10.1016\/j.ymthe.2017.06.008"},{"key":"9806_CR119","doi-asserted-by":"publisher","first-page":"2100","DOI":"10.1016\/j.ccell.2023.11.004","volume":"41","author":"E Bergaggio","year":"2023","unstructured":"Bergaggio E, Tai WT, Aroldi A, Mecca C, Landoni E, N\u00fcesch M, et al. ALK inhibitors increase ALK expression and sensitize neuroblastoma cells to ALK.CAR-T cells. Cancer Cell Cell Press. 2023;41:2100\u2013e211610. https:\/\/doi.org\/10.1016\/j.ccell.2023.11.004. [cited 2026 Mar 23];.","journal-title":"Cancer Cell Cell Press"},{"key":"9806_CR120","doi-asserted-by":"publisher","unstructured":"Fern\u00e1ndez-Aguilar LM, Vico-Barranco I, Arbulo-Echevarria MM, Aguado E. A Story of Kinases and Adaptors: The Role of Lck, ZAP-70 and LAT in Switch Panel Governing T-Cell Development and Activation. Biology (Basel). Multidisciplinary Digital Publishing Institute (MDPI). 2023;12:1163. https:\/\/doi.org\/10.3390\/BIOLOGY12091163. [cited 2026 May 31].","DOI":"10.3390\/BIOLOGY12091163"},{"key":"9806_CR121","doi-asserted-by":"publisher","unstructured":"Tousley AM, Rotiroti MC, Labanieh L, Rysavy LW, Kim WJ, Lareau C, et al. Co-opting signalling molecules enables logic-gated control of CAR T cells. Nature 2023 615:7952. Volume 615. Nature Publishing Group; 2023. pp. 507\u201316. [cited 2026 Feb 21]. https:\/\/doi.org\/10.1038\/s41586-023-05778-2.","DOI":"10.1038\/s41586-023-05778-2"},{"key":"9806_CR122","doi-asserted-by":"publisher","unstructured":"Vo MC, Tran VDH, Nguyen VT, Ruzimurodov N, Trung DT, Kim SK, et al. Challenges and limitations of chimeric antigen receptor T-cell therapies in solid tumors: why are approvals restricted to hematologic malignancies? J Hematol Oncol. Volume 18. BioMed Central Ltd; 2025. p. 91. [cited 2026 May 31]. https:\/\/doi.org\/10.1186\/S13045-025-01744-9.","DOI":"10.1186\/S13045-025-01744-9"},{"key":"9806_CR123","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/S12672-025-04195-3","volume":"17","author":"M Sheikh","year":"2025","unstructured":"Sheikh M, Madia D, Telrandhe UB, Bagga H, Deshmukh A. Advancing breast cancer treatment through dual targeting CAR T cell therapy. Discover Oncology. Springer Sci Bus Media B V. 2025;17:58. https:\/\/doi.org\/10.1007\/S12672-025-04195-3. [cited 2026 May 31];.","journal-title":"Springer Sci Bus Media B V"},{"key":"9806_CR124","doi-asserted-by":"publisher","unstructured":"Khodabandehloo E, Rayati M, Ahmadi E, Naghdibadi M, Moradi V, Ahmadbeigi N. Harnessing the potential of gene editing technology for CAR-T cell therapy of solid tumors. Inflamm Regen. BioMed Central Ltd; 2025;45:34. https:\/\/doi.org\/10.1186\/S41232-025-00398-X. [cited 2026 May 31].","DOI":"10.1186\/S41232-025-00398-X"},{"key":"9806_CR125","doi-asserted-by":"publisher","unstructured":"Alishah K, Birtel M, Masoumi E, Jafarzadeh L, Mirzaee HR, Hadjati J et al. CRISPR\/Cas9-mediated TGF\u03b2RII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro. J Translational Med 2021 19:1. BioMed Central. 2021;19:482\u2013. https:\/\/doi.org\/10.1186\/S12967-021-03146-0. [cited 2026 Jan 3].","DOI":"10.1186\/S12967-021-03146-0"},{"key":"9806_CR126","doi-asserted-by":"publisher","unstructured":"Shu R, Evtimov VJ, Hammett MV, Nguyen NYN, Zhuang J, Hudson PJ et al. Engineered CAR-T cells targeting TAG-72 and CD47 in ovarian cancer. Mol Ther Oncolytics. Cell Press; 2021;20:325\u201341. https:\/\/doi.org\/10.1016\/j.omto.2021.01.002. [cited 2026 Feb 21].","DOI":"10.1016\/j.omto.2021.01.002"},{"key":"9806_CR127","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1038\/CR.2016.81","volume":"26","author":"F Luo","year":"2016","unstructured":"Luo F, Qian J, Yang J, Deng Y, Zheng X, Liu J, et al. Bifunctional \u03b1HER2\/CD3 RNA-engineered CART-like human T cells specifically eliminate HER2\u2009+\u2009gastric cancer. Cell Res Nat Publishing Group. 2016;26:850. https:\/\/doi.org\/10.1038\/CR.2016.81. [cited 2026 Jan 6];.","journal-title":"Cell Res Nat Publishing Group"},{"key":"9806_CR128","doi-asserted-by":"publisher","unstructured":"Dai Z, Mu W, Zhao Y, Cheng J, Lin H, Ouyang K et al. T cells expressing CD5\/CD7 bispecific chimeric antigen receptors with fully human heavy-chain-only domains mitigate tumor antigen escape. Signal Transduct Target Ther. Signal Transduct Target Ther; 2022 [cited 2026 Feb 14];7. https:\/\/doi.org\/10.1038\/S41392-022-00898-Z.","DOI":"10.1038\/S41392-022-00898-Z"},{"key":"9806_CR129","doi-asserted-by":"publisher","unstructured":"Yang HR, Zhang YJ, Li YQ, Peng S, An R, Du NN, et al. Bispecific c-Met\/PD-1 CAR-T Cells Have Enhanced Therapeutic Effects on Solid Tumor. Technol Cancer Res Treat. Volume 24. SAGE Publications Inc.; 2025. p. 15330338251336850. [cited 2026 Mar 23]. https:\/\/doi.org\/10.1177\/15330338251336850.","DOI":"10.1177\/15330338251336850"},{"key":"9806_CR130","doi-asserted-by":"publisher","first-page":"1578","DOI":"10.1158\/0008-5472.CAN-15-2524","volume":"76","author":"X Liu","year":"2016","unstructured":"Liu X, Ranganathan R, Jiang S, Fang C, Sun J, Kim S, et al. A Chimeric Switch-Receptor Targeting PD1 Augments the Efficacy of Second-Generation CAR T Cells in Advanced Solid Tumors. Cancer Res Cancer Res. 2016;76:1578\u201390. https:\/\/doi.org\/10.1158\/0008-5472.CAN-15-2524. [cited 2026 Jan 8];.","journal-title":"Cancer Res Cancer Res"},{"key":"9806_CR131","unstructured":"Zhao W, Jia L, Zhang M, Huang X, Qian P, Tang Q et al. The killing effect of novel bi-specific Trop2\/PD-L1 CAR-T cell targeted gastric cancer. Am J Cancer Res. 2019;9:1846. https:\/\/pmc.ncbi.nlm.nih.gov\/articles\/PMC6726977\/. Accessed 23 Mar 2026. [cited 2026 Mar 23]."},{"key":"9806_CR132","doi-asserted-by":"publisher","DOI":"10.1186\/S12967-025-07278-5","author":"M Zhou","year":"2025","unstructured":"Zhou M, Xu L, Hu J, Chen W, Hong J, Wang M, et al. Metabolic reprogramming through PIM3 inhibition reverses hypoxia-induced CAR-T cell dysfunction in solid tumors. J Transl Med J Transl Med. 2025. https:\/\/doi.org\/10.1186\/S12967-025-07278-5. [cited 2025 Dec 29];23.","journal-title":"J Transl Med J Transl Med"},{"key":"9806_CR133","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/S43018-023-00573-4","volume":"4","author":"Y Xiong","year":"2023","unstructured":"Xiong Y, Taleb M, Misawa K, Hou Z, Banerjee S, Amador-Molina A, et al. c-Kit signaling potentiates CAR T cell efficacy in solid tumors by CD28- and IL-2-independent co-stimulation. Nat Cancer Nat Cancer. 2023;4:1001\u201315. https:\/\/doi.org\/10.1038\/S43018-023-00573-4. [cited 2026 Feb 21];.","journal-title":"Nat Cancer Nat Cancer"},{"key":"9806_CR134","doi-asserted-by":"publisher","DOI":"10.3390\/CELLS14120901","author":"DC Harrer","year":"2025","unstructured":"Harrer DC, Schlierkamp-Voosen T, Barden M, Pan H, Xydia M, Herr W, et al. Chimeric Antigen Receptor (CAR) T Cells Releasing Soluble SLAMF6 Isoform 2 Gain Superior Anti-Cancer Cell Functionality in an Auto-Stimulatory Fashion. Cells Cells. 2025. https:\/\/doi.org\/10.3390\/CELLS14120901. [cited 2026 Feb 21];14.","journal-title":"Cells Cells"},{"key":"9806_CR135","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1158\/2159-8290.CD-22-1350","volume":"14","author":"S L\u00f3pez-Cobo","year":"2024","unstructured":"L\u00f3pez-Cobo S, Fuentealba JR, Gueguen P, Bont\u00e9 PE, Tsalkitzi K, Chac\u00f3n I, et al. SUV39H1 Ablation Enhances Long-term CAR T Function in Solid Tumors. Cancer Discov Cancer Discov. 2024;14:120\u201341. https:\/\/doi.org\/10.1158\/2159-8290.CD-22-1350. [cited 2026 Jun 30];.","journal-title":"Cancer Discov Cancer Discov"},{"key":"9806_CR136","doi-asserted-by":"publisher","unstructured":"Tian X, Liu G, Wang Q, Zhang N, Shen Y, Du B et al. Genome editing or small molecule inhibition of KMT5A in CAR-T cells enhances antitumor immunity. J Immunother Cancer. BMJ Publishing Group Ltd; 2025;13:12160. https:\/\/doi.org\/10.1136\/JITC-2025-012160. [cited 2026 Jun 30].","DOI":"10.1136\/JITC-2025-012160"},{"key":"9806_CR137","doi-asserted-by":"publisher","first-page":"200962","DOI":"10.1016\/J.OMTON.2025.200962","volume":"33","author":"VJ Evtimov","year":"2025","unstructured":"Evtimov VJ, Nguyen NYN, Hammett MV, Pupovac A, Hudson PJ, Zhuang J, et al. CRISPR-Cas9 knockout of DGK\u03b1\/\u03b6 improves the anti-tumor activities of TAG-72 CAR-T cells in ovarian cancer. Mol Therapy Oncol Elsevier. 2025;33:200962. https:\/\/doi.org\/10.1016\/J.OMTON.2025.200962. [cited 2026 Jun 30];.","journal-title":"Mol Therapy Oncol Elsevier"},{"key":"9806_CR138","doi-asserted-by":"publisher","unstructured":"Wang H, Wang X, Ye X, Ju Y, Cao N, Wang S et al. Nonviral mcDNA-mediated bispecific CAR T cells kill tumor cells in an experimental mouse model of hepatocellular carcinoma. BMC Cancer. BioMed Central Ltd. 2022;22:814. https:\/\/doi.org\/10.1186\/S12885-022-09861-1. [cited 2025 Dec 29].","DOI":"10.1186\/S12885-022-09861-1"},{"key":"9806_CR139","doi-asserted-by":"publisher","first-page":"e011533","DOI":"10.1136\/jitc-2025-011533","volume":"13","author":"S Stucchi","year":"2025","unstructured":"Stucchi S, Borea R, Garcia-Recio S, Zingarelli M, R\u00e4dler PD, Camerini E, et al. B7-H3 and CSPG4 co-targeting as Pan-CAR-T cell treatment of triple-negative breast cancer. J Immunother Cancer BMJ. 2025;13:e011533. https:\/\/doi.org\/10.1136\/jitc-2025-011533. [cited 2026 Mar 23];. Publishing Group.","journal-title":"J Immunother Cancer BMJ"},{"key":"9806_CR140","doi-asserted-by":"publisher","first-page":"4365","DOI":"10.7150\/ijbs.63181","volume":"17","author":"Z Liang","year":"2021","unstructured":"Liang Z, Dong J, Yang N, Li S, Di, Yang ZY, Huang R, et al. Tandem CAR-T cells targeting FOLR1 and MSLN enhance the antitumor effects in ovarian cancer. Int J Biol Sci Int J Biol Sci. 2021;17:4365\u201376. https:\/\/doi.org\/10.7150\/ijbs.63181. [cited 2026 Mar 23];.","journal-title":"Int J Biol Sci Int J Biol Sci"},{"key":"9806_CR141","doi-asserted-by":"publisher","unstructured":"Fu Q, Zheng Y, Fang W, Zhao Q, Zhao P, Liu L, et al. RUNX-3-expressing CAR T cells targeting glypican-3 in patients with heavily pretreated advanced hepatocellular carcinoma: a phase I trial. EClinicalMedicine. Elsevier Ltd. 2023;63. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102175. [cited 2026 Mar 23].","DOI":"10.1016\/j.eclinm.2023.102175"},{"key":"9806_CR142","doi-asserted-by":"publisher","unstructured":"Brea EJ, Baldacci S, Savage N, Facchinetti F, Hinchey C, Chakravarti S et al. Systematic Engineering of TROP2-Targeted CAR T-Cell Therapy Overcomes Resistance Pathways in Solid Tumors. Cancer Immunol Res. American Association for Cancer Research Inc. 2025;13:1749\u201363. https:\/\/doi.org\/10.1158\/2326-6066.CIR-25-0527. [cited 2026 Mar 23].","DOI":"10.1158\/2326-6066.CIR-25-0527"},{"key":"9806_CR143","doi-asserted-by":"publisher","unstructured":"Mardiana S, Shestova O, Grupp SA, Ruella M, Barrett DM, Gill S. Repurposing Bi-Specific Chimeric Antigen Receptor (CAR) Approach to Enhance CAR T Cell Activity Against Low Antigen Density Tumors. Blood. Content Repository Only! 2021;138:1727. https:\/\/doi.org\/10.1182\/BLOOD-2021-146995. [cited 2026 Feb 21].","DOI":"10.1182\/BLOOD-2021-146995"},{"key":"9806_CR144","doi-asserted-by":"publisher","unstructured":"Dewaele L, Fernandes RA. Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review. Immunotherapy Advances. Volume 5. Oxford University Press; 2025. p. ltae005. [cited 2026 May 31]. https:\/\/doi.org\/10.1093\/IMMADV\/LTAE005.","DOI":"10.1093\/IMMADV\/LTAE005"},{"key":"9806_CR145","doi-asserted-by":"publisher","unstructured":"Dewaele L, Fernandes RA. Bispecific T-cell engagers for the recruitment of T cells in solid tumors: a literature review. Immunotherapy Advances. Oxford Academic. 2024;5. https:\/\/doi.org\/10.1093\/IMMADV\/LTAE005. [cited 2026 Feb 21].","DOI":"10.1093\/IMMADV\/LTAE005"},{"key":"9806_CR146","doi-asserted-by":"publisher","first-page":"1684655","DOI":"10.3389\/FIMMU.2025.1684655\/TEXT","volume":"16","author":"I Zagorac","year":"2025","unstructured":"Zagorac I, Ram\u00edrez-Fern\u00e1ndez \u00c1, Tapia-Galisteo A, Rubio-P\u00e9rez L, G\u00f3mez-Rosel M, Grau M, et al. mRNA-engineered T lymphocytes secreting bispecific T cell engagers with therapeutic potential in solid tumors. Front Immunol Front Media SA. 2025;16:1684655. https:\/\/doi.org\/10.3389\/FIMMU.2025.1684655\/TEXT.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR147","doi-asserted-by":"publisher","first-page":"2537","DOI":"10.1016\/j.ymthe.2022.05.011","volume":"30","author":"Y Yin","year":"2022","unstructured":"Yin Y, Rodriguez JL, Li N, Thokala R, Nasrallah MP, Hu L, et al. Locally secreted BiTEs complement CAR T cells by enhancing killing of antigen heterogeneous solid tumors. Mol Therapy Cell Press. 2022;30:2537\u201353. https:\/\/doi.org\/10.1016\/j.ymthe.2022.05.011. [cited 2026 Feb 21];.","journal-title":"Mol Therapy Cell Press"},{"key":"9806_CR148","doi-asserted-by":"publisher","unstructured":"Huang SW, Pan CM, Lin YC, Chen MC, Chen Y, Jan CI et al. BiTE-Secreting CAR\u2010\u03b3\u03b4T as a Dual Targeting Strategy for the Treatment of Solid Tumors. Advanced Science. John Wiley and Sons Inc; 2023;10:2206856. https:\/\/doi.org\/10.1002\/ADVS.202206856. [cited 2026 Jan 7].","DOI":"10.1002\/ADVS.202206856"},{"key":"9806_CR149","doi-asserted-by":"publisher","unstructured":"Porter CE, Rosewell Shaw A, Jung Y, Yip T, Castro PD, Sandulache VC et al. Oncolytic Adenovirus Armed with BiTE, Cytokine, and Checkpoint Inhibitor Enables CAR T Cells to Control the Growth of Heterogeneous Tumors. Mol Ther. Mol Ther. 2020;28:1251\u201362. https:\/\/doi.org\/10.1016\/J.YMTHE.2020.02.016. [cited 2026 Feb 21].","DOI":"10.1016\/J.YMTHE.2020.02.016"},{"key":"9806_CR150","doi-asserted-by":"publisher","first-page":"1037934","DOI":"10.3389\/FONC.2022.1037934\/TEXT","volume":"12","author":"Y Liu","year":"2022","unstructured":"Liu Y, Zheng Y, Deng T, Huang Y, Liu Z, Zhan B, et al. Oncolytic herpes simplex virus delivery of dual CAR targets of CD19 and BCMA as well as immunomodulators to enhance therapeutic efficacy in solid tumors combined with CAR T cell therapy. Front Oncol Front Media S A. 2022;12:1037934. https:\/\/doi.org\/10.3389\/FONC.2022.1037934\/TEXT.","journal-title":"Front Oncol Front Media S A"},{"key":"9806_CR151","doi-asserted-by":"publisher","unstructured":"Majzner RG, Rietberg SP, Sotillo E, Dong R, Vachharajani VT, Labanieh L, et al. Tuning the Antigen Density Requirement for CAR T Cell Activity. Cancer Discov. Volume 10. American Association for Cancer Research Inc.; 2020. p. 702. [cited 2026 Jun 30]. https:\/\/doi.org\/10.1158\/2159-8290.CD-19-0945.","DOI":"10.1158\/2159-8290.CD-19-0945"},{"key":"9806_CR152","doi-asserted-by":"publisher","unstructured":"Warmuth L, D\u00f6tsch S, Trebo M, Bellucci S, Engels S, Valdivia Manrique R et al. Balancing the efficacy and safety of chimeric antigen receptor T-cell therapy by affinity combination. Nature Communications. 2026 17:1. Nature Publishing Group; 2026;17:3413-. https:\/\/doi.org\/10.1038\/s41467-026-71354-7. [cited 2026 Jun 30].","DOI":"10.1038\/s41467-026-71354-7"},{"key":"9806_CR153","doi-asserted-by":"publisher","unstructured":"Yin X, He L, Guo Z. T-cell exhaustion in CAR-T-cell therapy and strategies to overcome it. Immunology. John Wiley and Sons Inc; 2023;169:400\u201311. https:\/\/doi.org\/10.1111\/IMM.13642. [cited 2026 Jun 30].","DOI":"10.1111\/IMM.13642"},{"key":"9806_CR154","doi-asserted-by":"publisher","unstructured":"Smirnov S, Zaritsky Y, Silonov S, Gavrilova A, Fonin A, Advancing. CAR-T Therapy for Solid Tumors: From Barriers to Clinical Progress. Biomolecules. Multidisciplinary Digital Publishing Institute (MDPI); 2025 [cited 2026 Jun 30];15:1407. https:\/\/doi.org\/10.3390\/BIOM15101407.","DOI":"10.3390\/BIOM15101407"},{"key":"9806_CR155","doi-asserted-by":"publisher","unstructured":"Peter J, Toppeta F, Trubert A, Danhof S, Hudecek M, D\u00e4ullary T, Multi-Targeting CAR-T, Karger AG. 2025;48:265\u201379. https:\/\/doi.org\/10.1159\/000543806. [cited 2026 Jun 30].","DOI":"10.1159\/000543806"},{"key":"9806_CR156","doi-asserted-by":"publisher","unstructured":"Zhang Z, Cui D, Wang H, Wu L, Liu X, Unleashing. CAR-T potential in solid tumors: overcoming intrinsic and extrinsic hurdles to improve therapy. Cancer Immunol Immunother. Springer Science and Business Media Deutschland GmbH. 2026;75:37. https:\/\/doi.org\/10.1007\/S00262-025-04278-8. [cited 2026 Jun 30].","DOI":"10.1007\/S00262-025-04278-8"},{"key":"9806_CR157","doi-asserted-by":"publisher","unstructured":"Liu G, Rui W, Zhao X, Lin X, Enhancing. CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. Cell Mol Immunol. Springer Nature; 2021;18:1085. https:\/\/doi.org\/10.1038\/S41423-021-00655-2. [cited 2026 Jun 30].","DOI":"10.1038\/S41423-021-00655-2"},{"key":"9806_CR158","doi-asserted-by":"publisher","unstructured":"Gumber D, Wang LD, Elsevier BV. 2022;77:103941. https:\/\/doi.org\/10.1016\/J.EBIOM.2022.103941. [cited 2026 Jun 30].","DOI":"10.1016\/J.EBIOM.2022.103941"},{"key":"9806_CR159","doi-asserted-by":"publisher","unstructured":"Kailayangiri S, Altvater B, Wiebel M, Jamitzky S, Rossig C. Overcoming Heterogeneity of Antigen Expression for Effective CAR T Cell Targeting of Cancers. Cancers (Basel). Volume 12. MDPI AG; 2020. p. 1075. [cited 2026 Jun 30]. https:\/\/doi.org\/10.3390\/CANCERS12051075.","DOI":"10.3390\/CANCERS12051075"},{"key":"9806_CR160","doi-asserted-by":"publisher","unstructured":"Yang Y, Vedvyas Y, Alcaina Y, Trumper SJ, Babu DS, Min IM et al. Affinity-tuned mesothelin CAR T cells demonstrate enhanced targeting specificity and reduced off-tumor toxicity. JCI Insight. American Society for Clinical Investigation; 2024;9:e186268. https:\/\/doi.org\/10.1172\/JCI.INSIGHT.186268. [cited 2026 Jun 30].","DOI":"10.1172\/JCI.INSIGHT.186268"},{"key":"9806_CR161","doi-asserted-by":"publisher","unstructured":"Liu XF, Onda M, Schlomer J, Bassel L, Kozlov S, Tai CH et al. Tumor resistance to anti-mesothelin CAR-T cells caused by binding to shed mesothelin is overcome by targeting a juxtamembrane epitope. Proc Natl Acad Sci U S A. National Acad Sci. 2024;121:e2317283121. https:\/\/doi.org\/10.1073\/PNAS.2317283121. [cited 2026 Jun 30].","DOI":"10.1073\/PNAS.2317283121"},{"key":"9806_CR162","doi-asserted-by":"publisher","unstructured":"Scholler J, Song A, Deshmukh M, Song D, June CH, Siegel DL. Engineering a Juxtamembrane-Targeting CAR T-Cell Against Mesothelin: A Novel Binder Resilient to Shed Antigen in Ovarian and Pancreatic Cancer. bioRxiv. Cold Spring Harbor Laboratory; 2025;2025.08.02.668276. https:\/\/doi.org\/10.1101\/2025.08.02.668276. [cited 2026 Jun 30].","DOI":"10.1101\/2025.08.02.668276"},{"key":"9806_CR163","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/S00018-021-04089-X","volume":"79","author":"Y Duan","year":"2021","unstructured":"Duan Y, Chen R, Huang Y, Meng X, Chen J, Liao C, et al. Tuning the ignition of CAR: optimizing the affinity of scFv to improve CAR-T therapy. Cell Mol Life Sci Springer Sci Bus Media Deutschland GmbH. 2021;79:14. https:\/\/doi.org\/10.1007\/S00018-021-04089-X. [cited 2026 Jun 30];.","journal-title":"Cell Mol Life Sci Springer Sci Bus Media Deutschland GmbH"},{"key":"9806_CR164","doi-asserted-by":"publisher","unstructured":"Hernandez-Lopez RA, Yu W, Cabral KA, Creasey OA, del Pilar Lopez Pazmino M, Tonai Y et al. T cell circuits that sense antigen density with an ultrasensitive threshold. Science. Am Assoc Advanc Sci. 2021;371:1166\u201371. https:\/\/doi.org\/10.1126\/SCIENCE.ABC1855.\u00a0[cited 2026 Jun 30].","DOI":"10.1126\/SCIENCE.ABC1855"},{"key":"9806_CR165","doi-asserted-by":"publisher","unstructured":"Picarda E, Galbo PM, Zong H, Rajan MR, Wallenius V, Zheng D, et al. The immune checkpoint B7-H3 (CD276) regulates adipocyte progenitor metabolism and obesity development. Sci Adv. Am Assoc Advanc Sci. 2022;8. https:\/\/doi.org\/10.1126\/SCIADV.ABM7012;SUBPAGE:STRING:FULL. [cited 2026 Jun 30].","DOI":"10.1126\/SCIADV.ABM7012;SUBPAGE:STRING:FULL"},{"key":"9806_CR166","doi-asserted-by":"publisher","first-page":"1396490","DOI":"10.3389\/FONC.2024.1396490\/FULL","volume":"14","author":"CJ Ferreri","year":"2024","unstructured":"Ferreri CJ, Bhutani M. Mechanisms and management of CAR T toxicity. Front Oncol Front Media SA. 2024;14:1396490. https:\/\/doi.org\/10.3389\/FONC.2024.1396490\/FULL.","journal-title":"Front Oncol Front Media SA"},{"key":"9806_CR167","doi-asserted-by":"publisher","first-page":"1746673","DOI":"10.3389\/FIMMU.2026.1746673\/TEXT","volume":"17","author":"GK Zhang","year":"2026","unstructured":"Zhang GK, Wang HM, Zhou F. Smart control of CAR-T cells: emerging strategies for safer and more effective cancer immunotherapy. Front Immunol Front Media SA. 2026;17:1746673. https:\/\/doi.org\/10.3389\/FIMMU.2026.1746673\/TEXT.","journal-title":"Front Immunol Front Media SA"},{"key":"9806_CR168","doi-asserted-by":"publisher","unstructured":"Wang RB, Wang X, Han KK, Chen GD, Yang YL, Xu X et al. Chimeric Antigen Receptor Natural Killer T-Cell Therapy for Tumors: Promise and Progress. Pathobiology. Pathobiology. 2026;1\u201313. https:\/\/doi.org\/10.1159\/000551197. [cited 2026 Jun 30].","DOI":"10.1159\/000551197"},{"key":"9806_CR169","doi-asserted-by":"publisher","unstructured":"Guo J, Zeng X, Zhu Y, Yang D, Zhao X. Mesothelin-based CAR-T cells exhibit potent antitumor activity against ovarian cancer. J Transl Med. BioMed Central Ltd. 2024;22:367. https:\/\/doi.org\/10.1186\/S12967-024-05174-Y. [cited 2026 Jun 30].","DOI":"10.1186\/S12967-024-05174-Y"},{"key":"9806_CR170","doi-asserted-by":"publisher","unstructured":"Qutaiba O, Allela B, Shareef A, Jyothi SR, Nayak PP, Janney JB et al. Engineering CAR T NK and NKT cell therapies to target cancer stem cells and overcome stem like resistance. Discover Oncology. 2025;17:1. Springer; 2025;17:113-. https:\/\/doi.org\/10.1007\/S12672-025-04276-3. [cited 2026 Jun 30].","DOI":"10.1007\/S12672-025-04276-3"},{"key":"9806_CR171","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1186\/S12935-025-03938-0","volume":"25","author":"J Zhu","year":"2025","unstructured":"Zhu J, Zhou J, Tang Y, Huang R, Lu C, Qian K, et al. Advancements and challenges in CAR-T cell therapy for solid tumors: A comprehensive review of antigen targets, strategies, and future directions. Cancer Cell Int BioMed. 2025;25:313. https:\/\/doi.org\/10.1186\/S12935-025-03938-0. [cited 2026 Jun 30];. Central Ltd.","journal-title":"Cancer Cell Int BioMed"}],"container-title":["Immunologic Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12026-026-09806-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12026-026-09806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T19:03:40Z","timestamp":1784055820000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12026-026-09806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,14]]},"references-count":171,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9806"],"URL":"https:\/\/doi.org\/10.1007\/s12026-026-09806-x","relation":{},"ISSN":["1559-0755"],"issn-type":[{"value":"1559-0755","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,14]]},"assertion":[{"value":"1 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.,","order":1,"name":"Ethics","label":"Ethical approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to publish","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Clinical trial number","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"70"}}